ERBB2 and breast carcinoma: We observed the levels of cfDNA were higher in TNBC patients compared to ER+ and HER2+ patients. We speculate that the lower levels of cfDNA in HR+ breast cancer compared with HER2+ and TNBC can be partly due to the lower cellular proliferation rates in this subtype. Our results are in agreement with studies by Magbanua et.